Article
A new kind of drug, a Raf kinase inhibitor, is well-tolerated and may prove effective in treating patients with metastatic melanoma, according to researchers from the Abramson Cancer Center of the University of Pennsylvania.
Exploring the Effects of Masks on Skin Physiology
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Clinical Pearls for Vitiligo and Pigmentation Complexities: Part 3
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Which Tax Treatment Is Best for Your Dermatology Practice?
Facing Challenges in Pediatric Plaque Psoriasis